Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Exploring the therapeutic potential of perinatal cell SECRETomes

Project description

Training on the therapeutic potential of perinatal cell secretomes

Over the past two decades, cells from human perinatal tissues have demonstrated pro-regenerative activities, showing promise in improving symptoms in animal models of myocardial infarction (MI), ischemic stroke (IS), and multiple sclerosis (MS). Cell-free therapies represent an innovative frontier in regenerative medicine, but there is a need for enhanced training for scientists to advance these therapies to clinical practice. With the support of the Marie Skłodowska-Curie Actions programme, the SECRET project will train doctoral candidates to explore the therapeutic potential of perinatal cell secretomes for treating MI, IS, and MS. It will involve the development and use of induced pluripotent stem cell (iPSC)-derived organoids and organ-on-a-chip models to identify the most effective perinatal cell secretomes in terms of immunomodulation, angiogenesis, anti-fibrotic, cardio-protective, and neurotrophic properties.

Objective

Over the past two decades, cells isolated from human perinatal (or birth-associated) tissues (amniotic membrane, umbilical cord tissue and cells from amniotic fluid), have been shown to provide tremendous pro-regenerative activities. Amongst others, the application of these cells or of components of their secretome, including extracellular vesicles (EVs), have been found to improve myocardial infarction (MI), ischemic stroke (IS) and multiple sclerosis (MS) symptoms in various animal models. Currently, cell-free therapies represent a frontier for innovation in regenerative medicine for clinical unmet needs, however, very few scientists are trained for their clinical translation. “Exploring the therapeutic potential of perinatal cell SECRETomes - SECRET” sets out with the ambition to train 10 doctoral candidates (DCs) to disentangle the inherent therapeutic potential of perinatal cell secretomes (either as a whole or as fractionated small EVs) in order to possibile translate novel biologics into the clinic. Their specific focus will be the characterisation, the delivery and the preclinical evaluation of these perinatal secretomes as an innovative therapeutic approaches for MI, IS and MS. To achieve this goal, Università Cattolica del Sacro Cuore (Prof. Ornella Parolini, Italy) unites internationally-renowned academic and non-academic institutions from Italy, The Netherlands, Germany, Belgium, Portugal and Switzerland, to deliver an inter-disciplinary programme that goes beyond current state-of-the-art research in next generation medicinal product development and validation. These include the development and use of iPSC-derived organoids and organ-on-a-chip models to identify the most efficient perinatal cell secretome in terms of immunomodulation, angiogenesis, anti-fibrotic, cardio-protective and neuro-trophic properties, as well as the assessment of their in vivo cardiac reparative and neuro-regenerative potential using novel delivery methods.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-DN-01

See all projects funded under this call

Coordinator

UNIVERSITA CATTOLICA DEL SACRO CUORE
Net EU contribution
€ 518 875,20
Address
LARGO GEMELLI 1
20123 MILANO
Italy
Region
Centro (IT) Lazio Roma
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (5)

Partners (5)